Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions Jan 4, 2024
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer Nov 27, 2023
Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update Nov 13, 2023
Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy Nov 2, 2023
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director Nov 1, 2023